1. Wongsurakiat P, Chitwarakorn N. Severe community-acquired pneumonia in general medical wards: outcomes and impact of initial antibiotic selection. BMC pulmonary medicine 2019; 19: 179.
2. Lanks CW, Musani AI, Hsia DW. Community-acquired Pneumonia and Hospital-acquired Pneumonia. The Medical clinics of North America 2019; 103: 487-501.
3. Chahin A, Opal SM. Severe Pneumonia Caused by Legionella pneumophila: Differential Diagnosis and Therapeutic Considerations. Infectious disease clinics of North America 2017; 31: 111-21.
4. Marti C, Garin N, Grosgurin O et al. Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis. Critical care (London, England) 2012; 16: R141.
5. Hraiech S, Alingrin J, Dizier S et al. Time to intubation is associated with outcome in patients with community-acquired pneumonia. PloS one 2013; 8: e74937.
6. Restrepo MI, Mortensen EM, Rello J et al. Late admission to the ICU in patients with community-acquired pneumonia is associated with higher mortality. Chest 2010; 137: 552-7.
7. Restrepo MI, Mortensen EM, Velez JA et al. A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. Chest 2008; 133: 610-7.
8. Wiseman LR, Wagstaff AJ, Brogden RN et al. Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 1995; 50: 73-101.
9. Dhillon S. Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections. Drugs 2018; 78: 1259-70.
10. Jaruratanasirikul S, Thengyai S, Wongpoowarak W et al. Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units. Antimicrobial agents and chemotherapy 2015; 59: 2995-3001.
11. Ramon-Lopez A, Allen JM, Thomson AH et al. Dosing regimen of meropenem for adults with severe burns: a population pharmacokinetic study with Monte Carlo simulations. The Journal of antimicrobial chemotherapy 2015; 70: 882-90.
12. Zhou QT, He B, Shen N et al. Meropenem Dosing Based on a Population Pharmacokinetic-Pharmacodynamic Model in Elderly Patients with Infection of the Lower Respiratory Tract. Drugs & aging 2017; 34: 115-21.
13. Conte JE, Jr., Golden JA, Kelley MG et al. Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem. International journal of antimicrobial agents 2005; 26: 449-56.
14. Cies JJ, Moore WS, 2nd, Enache A et al. Population Pharmacokinetics and Pharmacodynamic Target Attainment of Meropenem in Critically Ill Young Children. The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG 2017; 22: 276-85.
15. Usman M, Frey OR, Hempel G. Population pharmacokinetics of meropenem in elderly patients: dosing simulations based on renal function. European journal of clinical pharmacology 2017; 73: 333-42.
16. Alobaid AS, Wallis SC, Jarrett P et al. Effect of Obesity on the Population Pharmacokinetics of Meropenem in Critically Ill Patients. Antimicrobial agents and chemotherapy 2016; 60: 4577-84.
17. Doh K, Woo H, Hur J et al. Population pharmacokinetics of meropenem in burn patients. The Journal of antimicrobial chemotherapy 2010; 65: 2428-35.
18. Hanberg P, Öbrink-Hansen K, Thorsted A et al. Population Pharmacokinetics of Meropenem in Plasma and Subcutis from Patients on Extracorporeal Membrane Oxygenation Treatment. Antimicrobial agents and chemotherapy 2018; 62.
19. Kristoffersson AN, David-Pierson P, Parrott NJ et al. Simulation-Based Evaluation of PK/PD Indices for Meropenem Across Patient Groups and Experimental Designs. Pharmaceutical research 2016; 33: 1115-25.
20. Roberts JA, Abdul-Aziz MH, Lipman J et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. The Lancet Infectious diseases 2014; 14: 498-509.
21. Mendez A, Chagastelles P, Palma E et al. Thermal and alkaline stability of meropenem: degradation products and cytotoxicity. International journal of pharmaceutics 2008; 350: 95-102.
22. Jaruratanasirikul S, Sriwiriyajan S. Comparison of the pharmacodynamics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection. The Journal of antimicrobial chemotherapy 2003; 52: 518-21.
23. McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. International journal of antimicrobial agents 2008; 31: 345-51.
24. Tam VH, McKinnon PS, Akins RL et al. Pharmacodynamics of cefepime in patients with Gram-negative infections. The Journal of antimicrobial chemotherapy 2002; 50: 425-8.
25. Abdul-Aziz MH, Lipman J, Akova M et al. Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort. The Journal of antimicrobial chemotherapy 2016; 71: 196-207.
26. Veiga RP, Paiva JA. Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients. Critical care (London, England) 2018; 22: 233.
27. Shahbaz H, Gupta M. Creatinine Clearance. StatPearls. Treasure Island (FL): StatPearls Publishing
Copyright © 2021, StatPearls Publishing LLC., 2021.
28. Nunes MBG, Filho AC, Alvares VRC et al. CKD-EPI versus Cockcroft-Gault formula for predicting contrast-induced nephropathy following percutaneous coronary intervention in patients without significant renal impairment. Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology 2018; 37: 25-33.
29. Casals G, Hernández C, Hidalgo S et al. Development and validation of a UHPLC diode array detector method for meropenem quantification in human plasma. Clinical biochemistry 2014; 47: 223-7.
30. Zou L, Meng F, Hu L et al. A novel reversed-phase high-performance liquid chromatographic assay for the simultaneous determination of imipenem and meropenem in human plasma and its application in TDM. Journal of pharmaceutical and biomedical analysis 2019; 169: 142-50.
31. Wong G, Farkas A, Sussman R et al. Comparison of the accuracy and precision of pharmacokinetic equations to predict free meropenem concentrations in critically ill patients. Antimicrobial agents and chemotherapy 2015; 59: 1411-7.
32. Zhao W, Kaguelidou F, Biran V et al. External Evaluation of Population Pharmacokinetic Models of Vancomycin in Neonates: The transferability of published models to different clinical settings. British journal of clinical pharmacology 2013; 75: 1068-80.
33. Glen JB, Servin F. Evaluation of the predictive performance of four pharmacokinetic models for propofol. British journal of anaesthesia 2009; 102: 626-32.
34. Egi A, Fukuda H, Kawamoto M et al. [Preoperative prediction of creatinine clearance by using serum creatinine]. Masui The Japanese journal of anesthesiology 2004; 53: 1306-10.
35. Chung EK, Cheatham SC, Fleming MR et al. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Nonobese, Obese, and Morbidly Obese Patients. Journal of clinical pharmacology 2017; 57: 356-68.
36. Sjövall F, Alobaid AS, Wallis SC et al. Maximally effective dosing regimens of meropenem in patients with septic shock. The Journal of antimicrobial chemotherapy 2018; 73: 191-8.
37. Benítez-Cano A, Luque S, Sorlí L et al. Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial. Critical care (London, England) 2020; 24: 55.
38. Burger R, Guidi M, Calpini V et al. Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections. The Journal of antimicrobial chemotherapy 2018; 73: 3413-22.
39. Corcione S, D'Avolio A, Loia RC et al. Pharmacokinetics of meropenem in burn patients with infections caused by Gram-negative bacteria: Are we getting close to the right treatment? Journal of global antimicrobial resistance 2020; 20: 22-7.
40. Wunderink RG, Matsunaga Y, Ariyasu M et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. The Lancet Infectious diseases 2021; 21: 213-25.
41. Nguyen CP, Dan Do TN, Bruggemann R et al. Clinical cure rate and cost-effectiveness of carbapenem-sparing beta-lactams vs. meropenem for Gram-negative infections: A systematic review, meta-analysis, and cost-effectiveness analysis. International journal of antimicrobial agents 2019; 54: 790-7.
42. Ehmann L, Zoller M, Minichmayr IK et al. Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic/pharmacodynamic analysis. International journal of antimicrobial agents 2019; 54: 309-17.
43. Roberts JA, Udy AA, Jarrett P et al. Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients. The Journal of antimicrobial chemotherapy 2015; 70: 1495-502.
44. Motos A, Kuti JL, Li Bassi G et al. Is One Sample Enough? β-Lactam Target Attainment and Penetration into Epithelial Lining Fluid Based on Multiple Bronchoalveolar Lavage Sampling Time Points in a Swine Pneumonia Model. Antimicrobial agents and chemotherapy 2019; 63.
45. Neely MN, van Guilder MG, Yamada WM et al. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Therapeutic drug monitoring 2012; 34: 467-76.